LP
PGNX

LMR Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

LMR Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-27,822
Closed -$166K – 627
2015
Q1 		$166K Buy
+27,822
New +$175K 0.02% 364
2014
Q4 		– Sell
-56,338
Closed -$292K – 502
2014
Q3 		$292K Buy
+56,338
New +$281K 0.02% 218

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

LMR Partners's PGNX Position: Q2 2015 in Review

LMR Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2015, closing a stake of 27,822 shares — an estimated $166K sold.

LMR Partners first reported a position in PGNX in Q3 2014 and held it in 2 quarters. The position peaked at $292K in Q3 2014. 121 funds tracked by Wall St. Rank hold PGNX as of Q2 2015.

  • LMR Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • LMR Partners sold 27,822 Progenics Pharmaceuticals Inc shares in Q2 2015, an estimated $166K.
  • LMR Partners first reported a position in Progenics Pharmaceuticals Inc in Q3 2014 and held it in 2 quarters.
  • LMR Partners's Progenics Pharmaceuticals Inc position peaked at $292K in Q3 2014.
  • 121 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2015.

Based on LMR Partners's 13F filing for Q2 2015, filed 10 Aug 2015.